Adaptive Free Cash Flow Operating Cash Flow Ratio from 2010 to 2024

ADPT Stock  USD 5.94  0.21  3.66%   
Adaptive Biotechnologies Free Cash Flow Operating Cash Flow Ratio yearly trend continues to be comparatively stable with very little volatility. Free Cash Flow Operating Cash Flow Ratio will likely drop to 0.90 in 2024. From the period from 2010 to 2024, Adaptive Biotechnologies Free Cash Flow Operating Cash Flow Ratio quarterly data regression had r-value of (0.02) and coefficient of variation of  8.72. View All Fundamentals
 
Free Cash Flow Operating Cash Flow Ratio  
First Reported
2010-12-31
Previous Quarter
1.06842839
Current Value
0.9
Quarterly Volatility
0.09430035
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive Biotechnologies' main balance sheet or income statement drivers, such as Interest Income of 14.2 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 13.1 M, as well as many indicators such as Price To Sales Ratio of 3.95, Dividend Yield of 0.0 or PTB Ratio of 2.41. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.
  
Check out the analysis of Adaptive Biotechnologies Correlation against competitors.

Latest Adaptive Biotechnologies' Free Cash Flow Operating Cash Flow Ratio Growth Pattern

Below is the plot of the Free Cash Flow Operating Cash Flow Ratio of Adaptive Biotechnologies Corp over the last few years. It is Adaptive Biotechnologies' Free Cash Flow Operating Cash Flow Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow Operating Cash Flow Ratio10 Years Trend
Very volatile
   Free Cash Flow Operating Cash Flow Ratio   
       Timeline  

Adaptive Free Cash Flow Operating Cash Flow Ratio Regression Statistics

Arithmetic Mean1.08
Geometric Mean1.08
Coefficient Of Variation8.72
Mean Deviation0.05
Median1.07
Standard Deviation0.09
Sample Variance0.01
Range0.4204
R-Value(0.02)
Mean Square Error0.01
R-Squared0.0004
Significance0.95
Slope(0.0004)
Total Sum of Squares0.12

Adaptive Free Cash Flow Operating Cash Flow Ratio History

2024 0.9
2022 1.09
2021 1.32
2020 1.13
2019 0.95
2018 1.2

About Adaptive Biotechnologies Financial Statements

Adaptive Biotechnologies shareholders use historical fundamental indicators, such as Free Cash Flow Operating Cash Flow Ratio, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptive Biotechnologies' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptive Biotechnologies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Free Cash Flow Operating Cash Flow Ratio 1.07  0.90 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.